Veeva Systems

☆ Save On Wikipedia ↗
Veeva Systems Inc.
TypePublic benefit corporation
IndustrySoftware for life sciences
Founded2007 (2007)
Founders
Headquarters,
U.S.
Key people
ProductsSoftware
ServicesBusiness consulting
RevenueIncrease US$3.195 billion (FY 2026)
Increase US$916 million (FY 2026)
Increase US$908 million (FY 2026)
Total assetsIncrease US$8.979 billion (FY 2026)
Total equityIncrease US$7.214 billion (FY 2026)
Number of employees
7,928 (2026)
Websiteveeva.com
Footnotes
[1][2]

Veeva Systems Inc., headquartered in Pleasanton, California, provides cloud computing software, data, and consulting services for the life sciences industry.[1] Its products are used to track all aspects of drug development and pharmaceutical manufacturing.[1]

The company has 1,552 customers including Bayer, Boehringer Ingelheim, Eli Lilly and Company, Gilead Sciences, Merck & Co., Novartis, Alkermes plc, Alnylam Pharmaceuticals, bluebird bio, and Idorsia.[1] Its primary competitor for its customer relationship management software is Salesforce, which is partnered with IQVIA.[1]

History

Veeva was founded in 2007 by Peter Gassner and Matt Wallach.[2]

In 2011, the company introduced Veeva Vault, a content management system for the life sciences industry.[3]

In October 2013, Veeva became a public company via an initial public offering on the New York Stock Exchange.[4][5]

In February 2021, Veeva became the first publicly traded company to convert to a public benefit corporation.[6]

In 2025, Veeva ended its partnership with Salesforce, a competitor.[7]

Acquisitions

# Date Company Notes Ref.
1 October 2015 Zinc Ahead Content management software company [8]
2 October 2019 Crossix Medical privacy-safe patient data and analytics company [9]
3 November 2019 Physicians World Provider of business process outsourcing services [10]
4 August 2021 Learnaboutgmp Compliance training services for life sciences organizations [11]
5 December 2021 Veracity Logic Provider of cloud software for randomization and trial supply management [12]
6 March 2026 Ostro Patient and HCP engagement with AI agents for life sciences; price was $100 milllion [13]

References